Skip to main content
. 2022 Aug 16;9(1):e000857. doi: 10.1136/bmjgast-2021-000857

Figure 3.

Figure 3

Prevalence of prespecified medications among (A) patients in the PBC population (N=1963) or (B) the PBC-pruritus subpopulation (N=139) relative to the respective non-case populations*. *Ns for the non-case population differs between analysis A and B: non-cases for analysis A (PBC population) N=10 245 592; non-cases for analysis B (PBC-pruritus subpopulation) N=9 984 009. Prevalence of prespecified medications in the PBC population or the PBC-pruritus subpopulation, using prevalence in the non-case population as reference. iSPRs ˃1 imply greater medication prevalence in either of the PBC case populations versus the PBC non-case population. Crude point prevalence (%) and iSPRs (95% CIs) for each of the medications shown are also reported in table 2.iSPRs, indirect age-sex standardised prevalence ratios; PBC, primary biliary cholangitis; MMF, mycophenolate mofetil.